Cross-resistance between targeted therapies and immune checkpoint inhibitors in melanoma - VJOncology Grant McArthur, MBBS, FRACP, PhD, FAHMS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the importance of understanding the interaction between...

🎥Prof. Grant McArthur from Peter Mac (@petermaccc.bsky.social) highlights how targeted therapy reshapes the immune microenvironment in melanoma, impacting response to IO. Smarter sequencing is key!

Learn more here➡️https://buff.ly/huymybh

#Melanoma2025 #EADO2025 #Melsm #Skcsm #ImmunoOnc

Japanese and East Asia-specific guidelines for the management of melanoma - VJOncology Satoshi Fukushima, MD, PhD, Kumamoto University, Kumamoto, Japan, discusses differences in melanoma subtype and drug efficacy between Western countries and...

🎥Prof. Satoshi Fukushima highlights the need for region-specific melanoma guidelines—Japanese data show PD-1 monotherapy may outperform dual IO for BRAF WT melanoma:

➡️https://buff.ly/CdL2xV9⬅️

#Melanoma2025 #EADO2025 #melsm #skcsm #ImmunoOnc

Potential of ADCs in treating melanoma - VJOncology Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, reflects on the potential of antibody-drug conjugates (ADCs)...

🎥Professor Georgina V Long (@gvlongphdmd.bsky.social) highlights the promise of antibody-drug conjugates (ADCs) in melanoma but stresses payload choice & durability as key challenges:

➡️https://buff.ly/pn2alez⬅️

#Melanoma2025 #EADO2025 #ImmunoOnc #MelSM #Skcsm